Heineman Thomas Charles 4

What Happened

• Thomas C. Heineman, Chief Medical Officer of Oncolytics Biotech Inc. (ONCY), was granted a 260,000-share stock option award on June 1, 2026. The Form 4 reports an acquisition amount of $0 because this is a grant; the exercise price for the options is set equal to the Nasdaq Capital Market closing price on the grant date (see footnote F1), so there is no immediate intrinsic value at grant.

Key Details

• Transaction date: June 1, 2026; Form 4 filed June 3, 2026 (filing appears timely).
• Grant: 260,000 stock options reported as an Award/Grant (code A); reported acquisition price $0.
• Exercise price: equal to the Nasdaq closing price on June 1, 2026 (per footnote F1).
• Vesting: options vest in three equal annual installments; first tranche vests June 1, 2027, subject to continued service (per footnote F2).
• Shares owned after transaction: not disclosed in the provided filing.
• No 10b5-1 plan, tax-withholding sale, or sale of shares reported in this filing.

Context

• This filing reports a time-based option grant (a compensation award), not a purchase or sale of underlying shares. The grant gives the holder the right to buy up to 260,000 shares at the stated exercise price after vesting; it does not represent an immediate cash outlay or sale. Such awards are common for executives and reflect compensation/retention arrangements rather than direct market buying or selling.